Compare Strategy Inc. (MSTR) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Strategy Inc. vs TG Therapeutics Inc — how do they compare? Strategy Inc. trades at $95.06 (market cap $37.84B), while TG Therapeutics Inc trades at $49.72 (market cap $7.64B). The key difference: Strategy Inc. is far larger — about 5× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Strategy Inc. nearer its low. Which is the better fit depends on your goals.
| MSTR | TGTX | |
|---|---|---|
Market Cap | $37.84B | $7.64B |
Sector | Technology | Health |
52-Week High | $394.39 | $59.06 |
52-Week Low | $82.31 | $26.94 |
Enterprise Value | $56.61B | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTR trades at $95.25, down 2.14% with a bearish technical signal. The company reported Q2 2026 EPS of -$24.45, missing expectations of -$2.19, continuing a trend of significant earnings misses. Despite a 62% analyst buy rating and $210 consensus price target, fundamentals show deep losses with -$3.85B net income and -6,102.96% net margin in 2025. Recent news highlights Bitcoin-related volatility and strategic shifts in the company's treasury management approach.
The stock faces substantial fundamental challenges with persistent losses and negative cash flow from operations, though Wall Street maintains bullish long-term targets. Key risks include execution challenges, Bitcoin price exposure, and competitive pressures in the software analytics market. The disconnect between analyst optimism and operational performance creates significant uncertainty for investors.
TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.
Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Strategy Inc.
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
